Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis
BackgroundRoutine administration of adjuvant chemotherapy for stage IB non-small cell lung cancer (NSCLC) remains controversial. To our knowledge, no available studies have assessed the outcomes of chemotherapy in patients with stage IB NSCLC who had prior malignancies.MethodsPatients with pathologi...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.938195/full |
_version_ | 1817992941617020928 |
---|---|
author | Ke Zhou Ke Zhou Yaqin Zhao Linchuan Liang Linchuan Liang Jie Cao Jie Cao Huahang Lin Huahang Lin Zhiyu Peng Zhiyu Peng Jiandong Mei Jiandong Mei |
author_facet | Ke Zhou Ke Zhou Yaqin Zhao Linchuan Liang Linchuan Liang Jie Cao Jie Cao Huahang Lin Huahang Lin Zhiyu Peng Zhiyu Peng Jiandong Mei Jiandong Mei |
author_sort | Ke Zhou |
collection | DOAJ |
description | BackgroundRoutine administration of adjuvant chemotherapy for stage IB non-small cell lung cancer (NSCLC) remains controversial. To our knowledge, no available studies have assessed the outcomes of chemotherapy in patients with stage IB NSCLC who had prior malignancies.MethodsPatients with pathological stage IB NSCLC with previous malignancies who underwent surgery between 2004 and 2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The patients were categorized into chemotherapy and observation group based on whether they received adjuvant chemotherapy. Propensity score matching was performed to reduce confounding bias, and Kaplan–Meier curves and log-rank tests were used to compare overall survival (OS) and cancer-specific survival (CSS) between the two groups. Subgroup analyses of the matched cohorts were then conducted to evaluate the relationship between clinical features and chemotherapy.ResultsA total of 894 eligible patients were identified; 90 (10.1%) patients received postoperative chemotherapy. Patients who received adjuvant chemotherapy obtained obvious OS benefits compared with those who received observation alone (HR = 0.68, 95% CI: 0.48–0.97, P = 0.031). In addition, the 5-year OS rate and median OS time in the chemotherapy group were higher and longer, respectively. Although chemotherapy offered no obvious benefits for CSS (HR = 0.80, 95% CI: 0.57–1.14, P = 0.35), patients who received chemotherapy showed a better 5-year CSS rate. On subgroup analyses, a chemotherapy advantage was observed in advanced age (≥65 years, HR = 0.62, 95% CI: 0.38–0.99, P = 0.045). The same chemotherapy advantages were observed in patients diagnosed with higher histological grades (poorly differentiated to undifferentiated) (HR = 0.56, 95% CI: 0.33–0.96, P = 0.033) and tumor sizes >3.1–4 cm (HR = 0.57, 95% CI: 0.37–0.87, P = 0.010). Interestingly, NSCLC patients with previous malignancies originating from the kidney and bladder (HR = 0.34, 95% CI: 0.12–0.99, P = 0.049) showed a chemotherapy advantage. The same chemotherapy advantages were observed in patients diagnosed with NSCLC within 3 to 5 years after prior cancers (HR = 0.39, 95% CI: 0.16–0.98, P = 0.044) and with localized SEER stage of prior cancers (HR = 0.49, 95% CI: 0.29–0.86, P = 0.012).ConclusionThese findings indicate that adjuvant chemotherapy may improve long-term outcomes for stage IB NSCLC patients with previous malignancies. It is recommended that physicians consider the clinical features of previous cancers when making adjuvant chemotherapy decisions for these patients. |
first_indexed | 2024-04-14T01:33:00Z |
format | Article |
id | doaj.art-c14fa6f42f874d078d4091edc8ca8a68 |
institution | Directory Open Access Journal |
issn | 2234-943X |
language | English |
last_indexed | 2024-04-14T01:33:00Z |
publishDate | 2022-08-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Oncology |
spelling | doaj.art-c14fa6f42f874d078d4091edc8ca8a682022-12-22T02:20:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.938195938195Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysisKe Zhou0Ke Zhou1Yaqin Zhao2Linchuan Liang3Linchuan Liang4Jie Cao5Jie Cao6Huahang Lin7Huahang Lin8Zhiyu Peng9Zhiyu Peng10Jiandong Mei11Jiandong Mei12Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaCancer Center of West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaBackgroundRoutine administration of adjuvant chemotherapy for stage IB non-small cell lung cancer (NSCLC) remains controversial. To our knowledge, no available studies have assessed the outcomes of chemotherapy in patients with stage IB NSCLC who had prior malignancies.MethodsPatients with pathological stage IB NSCLC with previous malignancies who underwent surgery between 2004 and 2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The patients were categorized into chemotherapy and observation group based on whether they received adjuvant chemotherapy. Propensity score matching was performed to reduce confounding bias, and Kaplan–Meier curves and log-rank tests were used to compare overall survival (OS) and cancer-specific survival (CSS) between the two groups. Subgroup analyses of the matched cohorts were then conducted to evaluate the relationship between clinical features and chemotherapy.ResultsA total of 894 eligible patients were identified; 90 (10.1%) patients received postoperative chemotherapy. Patients who received adjuvant chemotherapy obtained obvious OS benefits compared with those who received observation alone (HR = 0.68, 95% CI: 0.48–0.97, P = 0.031). In addition, the 5-year OS rate and median OS time in the chemotherapy group were higher and longer, respectively. Although chemotherapy offered no obvious benefits for CSS (HR = 0.80, 95% CI: 0.57–1.14, P = 0.35), patients who received chemotherapy showed a better 5-year CSS rate. On subgroup analyses, a chemotherapy advantage was observed in advanced age (≥65 years, HR = 0.62, 95% CI: 0.38–0.99, P = 0.045). The same chemotherapy advantages were observed in patients diagnosed with higher histological grades (poorly differentiated to undifferentiated) (HR = 0.56, 95% CI: 0.33–0.96, P = 0.033) and tumor sizes >3.1–4 cm (HR = 0.57, 95% CI: 0.37–0.87, P = 0.010). Interestingly, NSCLC patients with previous malignancies originating from the kidney and bladder (HR = 0.34, 95% CI: 0.12–0.99, P = 0.049) showed a chemotherapy advantage. The same chemotherapy advantages were observed in patients diagnosed with NSCLC within 3 to 5 years after prior cancers (HR = 0.39, 95% CI: 0.16–0.98, P = 0.044) and with localized SEER stage of prior cancers (HR = 0.49, 95% CI: 0.29–0.86, P = 0.012).ConclusionThese findings indicate that adjuvant chemotherapy may improve long-term outcomes for stage IB NSCLC patients with previous malignancies. It is recommended that physicians consider the clinical features of previous cancers when making adjuvant chemotherapy decisions for these patients.https://www.frontiersin.org/articles/10.3389/fonc.2022.938195/fullchemotherapystage IBnon-small cell lung cancerprevious malignancySEER |
spellingShingle | Ke Zhou Ke Zhou Yaqin Zhao Linchuan Liang Linchuan Liang Jie Cao Jie Cao Huahang Lin Huahang Lin Zhiyu Peng Zhiyu Peng Jiandong Mei Jiandong Mei Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis Frontiers in Oncology chemotherapy stage IB non-small cell lung cancer previous malignancy SEER |
title | Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis |
title_full | Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis |
title_fullStr | Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis |
title_full_unstemmed | Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis |
title_short | Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis |
title_sort | adjuvant chemotherapy may improve long term outcomes in stage ib non small cell lung cancer patients with previous malignancies a propensity score matched analysis |
topic | chemotherapy stage IB non-small cell lung cancer previous malignancy SEER |
url | https://www.frontiersin.org/articles/10.3389/fonc.2022.938195/full |
work_keys_str_mv | AT kezhou adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT kezhou adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT yaqinzhao adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT linchuanliang adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT linchuanliang adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT jiecao adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT jiecao adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT huahanglin adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT huahanglin adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT zhiyupeng adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT zhiyupeng adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT jiandongmei adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis AT jiandongmei adjuvantchemotherapymayimprovelongtermoutcomesinstageibnonsmallcelllungcancerpatientswithpreviousmalignanciesapropensityscorematchedanalysis |